Taysha Gene Therapies, Inc. TSHA 深 沪
等待开盘 11-10 09:30:00 美东时间
4.37
+0.040
+0.92%
华盛通- 最 高4.53
- 今 开4.41
- 成交量 335.72万股
- 最 低 4.25
- 昨 收 4.33
- 总市值 14.24亿
- 52周最高 7.30
- 市盈率 静 --
- 换手率 1.03%
- 52周最低 3.455
- 委 比 -7.97%
- 总股本 3.26亿
- 历史最高 33.35
- 量 比 0.95
- 振 幅 6.47%
- 历史最低 0.50
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted 25,000 RSUs to two new employees under its 2023 Inducement Plan, vesting over four years, to attract talent. The company focuses on developing AAV-based gene therapies for severe CNS disorders, with a lead program targeting Rett syndrome.
11-06 13:00
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
<p>Taysha Gene Therapies, Inc. will report its third-quarter 2026 financial results and host a corporate update conference call and webcast on November 12, 2026, at 8:30 AM ET. The live webcast and replay will be available on the company’s website. Taysha focuses on advancing AAV-based gene therapies for severe CNS diseases, with its lead program TSHA-102 targeting Rett syndrome. The company aims to address unmet medical needs and improve patient...
11-05 13:00
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supportin...
10-01 20:07
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies announced multiple presentations on its TSHA-102 program for Rett syndrome at the 55th Child Neurology Society Annual Meeting in Montreal. The oral and poster presentations will highlight safety and efficacy data from the REVEAL trial, as well as insights into novel study designs and assessment tools. TSHA-102 is an investigational gene therapy delivering a functional MECP2 gene to address the genetic root cause of Rett synd...
10-01 12:00
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
09-17 22:08
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted 5 new employees 314,000 RSUs and options to purchase 92,400 shares under its 2023 Inducement Plan. The RSUs vest over 4 years, and the stock options have an exercise price of $5.70, vesting similarly with a 10-year term. The company focuses on AAV-based gene therapies for CNS diseases.
09-04 12:00
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.
08-12 20:01
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.
08-12 04:00
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have entered into a commercial supply agreement for TSHA-102, a gene therapy for Rett syndrome. Catalent will serve as Taysha's primary manufacturer following potential FDA approval, leveraging its expertise in gene therapy manufacturing. This partnership aims to secure long-term commercial production capacity and scalable supply to meet future demand. Rett syndrome is a rare neurodevelopmental disorder caused b...
08-03 12:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
